drugset / Trial / NCT00681395
Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium
RandomizedCrossoverOpen-labelTreatment
Summary
To evaluate safety and compare the pharmacokinetic parameters from the fixed dose combination ABT-143 relative to that from the co-administration of the two monotherapies.
Timeline
- Start
- 2008-05
- Primary completion
- 2008-08
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABT-143 | Unknown | 5 mg | — |
| Subject | ABT-143 | Unknown | 20 mg | — |
| Subject | ABT-143 | Unknown | 45 mg | — |
| Subject | ABT-143 | Unknown | 135 mg | — |
| Comparator | ABT-335 | Small molecule | 45 mg | — |
| Comparator | ABT-335 | Small molecule | 135 mg | — |
| Comparator | Rosuvastatin | Small molecule | 5 mg | — |
| Comparator | Rosuvastatin | Small molecule | 20 mg | — |
Indications
No indication recorded.